Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

279
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
279
Global Climate Change01:50

Global Climate Change

29.1K
Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.
29.1K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

21
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
21
Ideal Solutions02:24

Ideal Solutions

22.7K
According to Raoult’s law, the partial vapor pressure of a solvent in a solution is equal or identical to the vapor pressure of the pure solvent multiplied by its mole fraction in the solution. However, Raoult's Law is only valid for ideal solutions. For a solution to be ideal, the solvent-solute interaction must be just as strong as a solvent-solvent or solute-solute interaction. This suggests that both the solute and the solvent would use the same amount of energy to escape to the...
22.7K
General Properties of Solutions02:12

General Properties of Solutions

36.2K
Many common substances around us exist as a solution, such as ocean water, air, and gasoline. All solutions are mixtures of substances that are composed of varying amounts of two or more types of atoms or molecules. A mixture with a non-uniform composition is a heterogeneous mixture, whereas a mixture with a uniform composition is a homogeneous mixture. The components that make the homogeneous mixture are evenly spread out and thoroughly mixed. 
36.2K
Solution Formation02:16

Solution Formation

38.2K
There is no one solvent that can dissolve every type of solute. Some substances that readily dissolve in a certain solvent might be insoluble in a different solvent. A simple way to predict which substances dissolve in which solvent is the phrase "like dissolves like". This means that polar substances, such as salt and sugar, dissolve in a polar substance like water. In contrast, non-polar substances are more soluble in non-polar solvents such as carbon tetrachloride.
This selective...
38.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linerixibat: First Approval.

Drugs·2026
Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026
Same author

Guselkumab: Pediatric First Approval.

Paediatric drugs·2026
Same author

Taletrectinib: First Approval.

Drugs·2025
Same author

Trastuzumab Rezetecan: First Approval.

Drugs·2025
Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025

Related Experiment Video

Updated: Feb 14, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K

Netarsudil Ophthalmic Solution 0.02%: First Global Approval.

Sheridan M Hoy1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 18, 2018
PubMed
Summary
This summary is machine-generated.

Netarsudil ophthalmic solution 0.02% is a new treatment for lowering high intraocular pressure (IOP) in glaucoma patients. This Rho-associated protein kinase inhibitor increases fluid drainage from the eye.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
2-Vessel Occlusion/Hypotension: A Rat Model of Global Brain Ischemia
09:29

2-Vessel Occlusion/Hypotension: A Rat Model of Global Brain Ischemia

Published on: June 22, 2013

20.7K

Related Experiment Videos

Last Updated: Feb 14, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
2-Vessel Occlusion/Hypotension: A Rat Model of Global Brain Ischemia
09:29

2-Vessel Occlusion/Hypotension: A Rat Model of Global Brain Ischemia

Published on: June 22, 2013

20.7K

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Glaucoma Research

Background:

  • Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma.
  • Current treatments aim to reduce IOP by decreasing aqueous humor production or increasing outflow.
  • Netarsudil ophthalmic solution 0.02% represents a novel therapeutic approach targeting trabecular meshwork outflow.

Purpose of the Study:

  • To summarize the development milestones of netarsudil ophthalmic solution 0.02% (Rhopressa®).
  • To highlight the drug's approval for reducing elevated IOP in open-angle glaucoma and ocular hypertension.
  • To provide an overview of the mechanism of action and administration of netarsudil 0.02%.

Main Methods:

  • Review of clinical development phases and regulatory submissions.
  • Description of netarsudil's mechanism as a Rho-associated protein kinase inhibitor.
  • Summary of approved dosage and administration guidelines.

Main Results:

  • Netarsudil ophthalmic solution 0.02% has received US FDA approval.
  • The drug is indicated for reducing elevated intraocular pressure.
  • Ongoing Phase III and Phase II trials are being conducted in the EU and Japan, respectively.

Conclusions:

  • Netarsudil 0.02% offers a new therapeutic option for managing open-angle glaucoma and ocular hypertension.
  • Its unique mechanism of increasing trabecular outflow through the trabecular meshwork differentiates it from existing treatments.
  • The drug's development signifies a significant advancement in glaucoma pharmacotherapy.